Cart is empty The U.S. Food and Drug Administration has approved Phathom Pharmaceuticals’ Voquezna (vonoprazan), a novel potassium-competitive acid blocker, as a new treatment for adults for with all grades of erosive esophagitis or erosive gastroesophageal reflux disease (GERD).
Leave A Comment